Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Immunotherapy for Renal Cell Carcinoma
NCT07510334Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2026
- Primary completion
- Aug 2033
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter in clear cell renal cell carcinoma (ccRCC), sponsored by Mayo Clinic. Primary endpoint: Objective Response Rate up to 5 years. Started Apr 2026; status: recruiting.
02
Drugs
recombinant vesicular stomatitis virus-expressing human interferon beta + sodium-iodide symporter
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07510334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510334.